Main Article Content

Nigel S B Rawson
Winanne Downey
Colleen J Maxwell
Roy West





Abstract 43 | PDF Downloads 26


1. West R, Sherman GJ, Downey W. A record linkage study of valproate and malformations in Saskatchewan. Can J Public Health 1985;76:226-8.
2. International Society for Pharmacoepidemiology. Bethesda, MD: International Society for Pharmacoepidemiology, 2011. http://www.pharmacoepi.org/ (January 27, 2011).
3. Tilson HH. Getting down to bases – record linkage in Saskatchewan. Can J Public Health 1985;76:222-3.
4. Malcolm E, Downey W, Strand LM, McNutt M, West R. Saskatchewan Health’s linkable data bases and pharmacoepidemiology. Post Market Surveill 1993;6:175-264.
5. Downey W, Stang MR, Beck P, Osei W, Nichol JL. Health services databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Chichester: Wiley, 2005:295-310.
6. Health services databases: information document. Regina: Saskatchewan Ministry of Health, November 2010. http://www.health.gov.sk.ca/Default.aspx?DN=21 03410e-ad99-4bf5-ba42-dc07b16f45a6 (January 27, 2011).
7. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
8. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing 1996;25:273-8.
9. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J 2006;174:169- 74.
10. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and non-users of non-steroidal antiinflammatory drugs in Saskatchewan, Canada, 1983. J Clin Epidemiol 1988;41:35-45.
11. Ray WA, Varas-Lorenzo C, Chung C, et al. Cardiovascular risks of non-steroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2:155-63.
12. Beck P, Wysowski D, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56:280-5.
13. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with non-adherence to statin therapy. Pharmacotherapy 2005;25:1035-43.
14. Rawson NSB, Rutledge Harding S, Malcolm E, Lueck L. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 1998;51:1343-55.
15. Walker AM, Szneke P, Bianchi Weatherby L, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999;107:356-62.
16. Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer’s disease. Pharmacoepidemiol Drug Saf 2010;19: 670-9.
17. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects – advantages and disadvantages. Nat Clin Pract Rheumatol 2007;3:725-32.
18. Black C, McGrail K, Fooks C, Baranek P, Maslove L. Data, data, everywhere…: improving access to population health and health services research data in Canada – final report. Vancouver: Centre for Health Services and Policy Research, April 2005: 40. http://www.chspr.ubc.ca/files/publications/2005/chspr05-12R.pdf (January 27, 2011).
19. Rawson NSB. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example. Pharmacoepidemiol Drug Saf 2009;18:1072-9.
20. Rawson NSB, D’Arcy C. Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan. Pharmacoepidemiol Drug Saf 1998;7:389-98.
21. Liu L, Reeder B, Shuaib A, Mazagri R. Validity of stroke diagnosis on hospital discharge records in Saskatchewan, Canada: implications for stroke surveillance. Cerebrovasc Dis 1999;9:224-30.
22. Rawson NSB, Robson DL. Concordance on the recording of cancer in the Saskatchewan Cancer Agency registry, hospital charts and death registrations. Can J Public Health 2000;91:390- 3.
23. West SL, Richter A, Melfi CA, McNutt M, Nennstiel ME, Mauskopf JA. Assessing the Saskatchewan database for outcomes research studies of depression and its treatment. J Clin Epidemiol 2000; 53:823-31.
24. Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan hospital automated database. Pharmacoepidemiol Drug Saf 2008;17:842-52.
25. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 2001;10:407-10.
26. Tricco AC, Pham B, Rawson NSB. Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions. J Clin Epidemiol 2008;61:192-7.
27. Proceedings of an International Symposium on Drug Database Uses, Regina, Canada, November 7-8, 1984. Regina: Saskatchewan Health, 1985.
28. CAPT/ACTP: Canadian Association for Population Therapeutics. Edmonton, AB: Canadian Association for Population Therapeutics, 2011. http://www.capt-actp.com/ (January 27, 2011).
29. Rawson NSB, De Souza LR. Epidemiology in the pharmaceutical industry: a Canadian perspective. Pharmacoepidemiol Drug Saf 2006;15:758-62.
30. Drug Safety and Effectiveness Network (DSEN). Ottawa: Canadian Institutes of Health Research, 2010. http://www.cihrirsc. gc.ca/e/40269.html (January 27, 2011).
31. Rawson NSB. Ethical issues in pharmacoepidemiologic research using Saskatchewan administrative health care utilization data. Pharmacoepidemiol Drug Saf 2001;10:607-12.